logo
SamsungBioepisandATLATLSignMemorandumofUnderstanding(MoU)toAccelerateEarly-StageBiotechInnovationinAsia-Pacific
===2026/4/29 13:08:02===
de at ATLATL’s incubation center with access to world-class resources, infrastructure, and expertise to accelerate their growth and development.

About Samsung Bioepis Co., Ltd.

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. As a wholly owned subsidiary of Samsung Epis Holdings, Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, endocrinology. For more information, please visitwww.samsungbioepis.comand follow us onLinkedInandX.

About ATLATL

As a global innovation platform for life science research and development, ATLATL has established research centers
=*=*=*=*=*=
当前为第3/5页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页